Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic Malignancies

NCT05320809 is registered in ClinicalTrials.gov with 3D Medicines as lead sponsor.

NCT NCT05320809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05320809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Immunogenicity of 3D189 in Patients With Hematologic Malignancies
Lead sponsor
3D Medicines
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2022
Completion date
November 4, 2025
Enrollment
16 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, higher-risk myelodysplastic syndrome, multiple myeloma, non-hodgkin lymphoma